MedTrace Logo

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

NCT06348173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2024-04-04

No results posted yet for this study

Summary

The aim of this retrospective observational study is to compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original randomized clinical trials.

This study will be performed using the charts of the patients.

Conditions

Interventions

DRUG

Mepolizumab

Compare the response to mepolizumab and benralizumab before and after treatment

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Université de Montréal

    lead OTHER

Principal Investigators

  • Catherine Lemiere, MD · Université de Montréal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06348173 on ClinicalTrials.gov